
Few ailments have frustrated medical science and the pharmaceutical industry for years on end in the way Alzheimer's has, as many have tried – and failed – to develop just one efficient treatment for the disease.
For this reason, the so-called Elad trial, which tests Novo Nordisk's liraglutide, which by the name of Victoza is already a well-established treatment for type II diabetes, as a treatment for Alzheimer's disease.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app